Recent patents on endocrine, metabolic & immune drug discovery最新文献_第10页

Cancer therapy based on a mechanism of action for controlling the immune system and the resulting patent portfolio. 基于控制免疫系统的作用机制和由此产生的专利组合的癌症治疗。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-12-31 DOI: 10.2174/1872214811307010001

V. C. Goswitz, Z. Sawicki

引用次数: 6

Diabetic nephropathy: causes and managements. 糖尿病肾病:原因和管理。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-12-31 DOI: 10.2174/1872214811307010057

Y. Tripathi, Durgavati Yadav

引用次数: 27

tPA in the central nervous system: relations between tPA and cell surface LRPs. 中枢神经系统tPA: tPA与细胞表面lrp的关系。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-12-31 DOI: 10.2174/1872214811307010065

S. Ortolano, C. Spuch

{"title":"tPA in the central nervous system: relations between tPA and cell surface LRPs.","authors":"S. Ortolano, C. Spuch","doi":"10.2174/1872214811307010065","DOIUrl":"https://doi.org/10.2174/1872214811307010065","url":null,"abstract":"A growing body of evidence has implicated the plasminogen activating system in various aspects of neurophysiology and pathophysiology. In ischemic stroke, blood-brain barrier (BBB) regulations, typically involving matrix metalloproteinases (MMPs), inhibitors tissue inhibitors of metalloproteinases (TIMPs) and the low density lipoprotein receptor- related protein/alpha 2-macroglobulin receptor (LRPs) as mediators became interesting since tissue plasminogen activator (tPA)-related BBB breakdown with risk of secondary hemorrhage was considered to involve these mediators too. The mechanism by which tPA implements its actions within the central nervous system (CNS) has been the topic of much controversy. Binding of plasminogen to surfaces is of crucial importance in regulating the function of this system. tPA can modulate permeability of the neurovascular unit in physiological conditions and pathological events exacerbating injury in ischemic stroke, vascular dementia, traumatic brain injury or neurotoxic events. The plasminogen activating enzyme system is widely appreciated for its role in fibrinolysis and thrombolysis and in other areas related to remodelling of the extracellular matrix. However, this enzyme system also has a major impact in the central nervous system under pathological circumstances. The aim of this review is to revise the last patents and news to understand the mechanism by which t-PA modulates BBB permeability.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"14 1","pages":"65-76"},"PeriodicalIF":0.0,"publicationDate":"2012-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83650299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Metabolic syndrome, its pathophysiology and the role of melatonin. 代谢综合征的病理生理及褪黑素的作用。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-12-31 DOI: 10.2174/187221413804660953

V. Srinivasan, Y. Ohta, J. Espino, J. Pariente, Ana B. Rodríguez, M. Mohamed, R. Zakaria

{"title":"Metabolic syndrome, its pathophysiology and the role of melatonin.","authors":"V. Srinivasan, Y. Ohta, J. Espino, J. Pariente, Ana B. Rodríguez, M. Mohamed, R. Zakaria","doi":"10.2174/187221413804660953","DOIUrl":"https://doi.org/10.2174/187221413804660953","url":null,"abstract":"Metabolic syndrome (MetS) is characterised by symptoms of obesity, insulin resistance, hypertension, dyslipidemia and diabetes mellitus. The pathophysiological mechanisms involved in MetS are complex and involved dysregulation of many biochemical and physiological regulatory mechanisms of the body. Elevated levels of low density lipoproteins like VLDL, and LDL with reduction of HDL seen in patients with MetS contribute to atherogenic dyslipedemia. Melatonin has been suggested to be effective in improving MetS through its anti-hyperlipidemic action. Melatonin reduced both adiposity, and body weight in experimental animal studies and also attenuated weight gain and obesityinduced metabolic alterations and this effect of melatonin is attributed to its anti-oxidative effects. Melatonin administration has been shown to inhibit insulin release by acting through both MT1 and MT2 melatonin receptors present in pancreatic β-cells. Melatonin also increased insulin sensitivity and glucose tolerance in animals fed with either high fat or high sucrose diet. Melatonin exerts most of its beneficial actions by acting through MT1 and MT2 melatonin receptors present in various tissues of the body and some of the metabolic actions of melatonin have been blocked by melatonin antagonist like luzindole. Ramelteon, the newly available melatonin agonist will also have more promising role in the control of MetS. The numbers of patents are available with regard to treatment of MetS. Drug related to antidepressant fluoxetine is used for treatment of MetS (US Patent No. 2008001400450). Anti-oxidants like S-adenosyl-methionine, Vitamin E, and Vitamin C have been found beneficial in treating MetS (US Patent No. 8063024). Melatonin being a powerful Antioxidant will have a promising role in treating patients with metabolic syndrome.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"69 1","pages":"11-25"},"PeriodicalIF":0.0,"publicationDate":"2012-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84862481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 72

Anti-allergic potential of herbs and herbal natural products - activities and patents. 草药和天然草药产品的抗过敏潜力-活性和专利。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-12-31 DOI: 10.2174/1872214811307010026

B. Cota, C. M. Bertollo, D. D. de Oliveira

{"title":"Anti-allergic potential of herbs and herbal natural products - activities and patents.","authors":"B. Cota, C. M. Bertollo, D. D. de Oliveira","doi":"10.2174/1872214811307010026","DOIUrl":"https://doi.org/10.2174/1872214811307010026","url":null,"abstract":"The increase of allergic diseases has accompanied the global population growth and the major challenge is to reduce morbidity. The currently available treatments present limitations regarding efficacy and safety. Hence, patients with chronic allergic conditions seek alternatives to achieve better control of symptoms. Many natural products have been identified as potential anti-allergic agents. In addition, plant formulations have demonstrated, in general, to be safe in clinical trials and demonstrate additional effects along with Western medicines such as synergism and modulation of the immune system. It is known that plants represent a source of new therapeutic agents and some of them have shown mechanisms of action similar to synthetic agents. However, in general, herbs and their combination are patented mainly by Asian countries to be used in food and drinks or cosmetics and dietary supplements and the anti-allergic mechanisms of action are not yet fully elucidated. In this review, we highlight relevant patent and studies with cultivated plants, plant formulations, and secondary metabolites that have been evaluated with respect to its anti-allergic potential.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"12 1","pages":"26-56"},"PeriodicalIF":0.0,"publicationDate":"2012-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88558185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Affective disorder and hyperandrogenism. 情感性障碍和高雄激素症。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-12-31 DOI: 10.2174/1872214811307010077

Celen Zerouni, E. Kummerow, M. Martínez, A. Díaz, Uribe Ezequiel, R. Wix-Ramos

引用次数: 4

HMGB-1 as a target for inflammation controlling. HMGB-1作为炎症控制的靶点。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-09-01 DOI: 10.2174/187221412802481784

Jose A Nogueira-Machado, Caroline M de Oliveira Volpe

{"title":"HMGB-1 as a target for inflammation controlling.","authors":"Jose A Nogueira-Machado, Caroline M de Oliveira Volpe","doi":"10.2174/187221412802481784","DOIUrl":"https://doi.org/10.2174/187221412802481784","url":null,"abstract":"In the present study, we evaluated recent patents that describe products or methods able to down-regulate the pro-inflammatory action of HMGB-1, also called as amphoterin. High Mobility Group Box-1 (HMGB-1) has been implicated in the pathogenesis of inflammatory diseases. HMGB-1 has been proposed to be a crucial mediator in the pathogenesis of many diseases including sepsis, arthritis, cancer, autoimmunity diseases and diabetes. It has been suggested that HMGB-1 itself can signal through RAGEs (receptor for advanced glycation end products) and through the Toll-Like Receptors TLR2 and TLR4. Activation of these receptors results ultimately in the activation of Nuclear Factor-kappaB (NFkappaB), inducing the up-regulation of leukocyte adhesion molecules, production of pro-inflammatory cytokines and angiogenic factors in both hematopoietic and endothelial cells, thereby promoting inflammation. There are several patents proposed for controlling the production, secretion and neutralization of HMGB-1 and consequently the inflammatory process. We have divided the patents in six groups based on mechanism of action. The group 1 is associated with inhibition of HMGB-1 using anti-HMGB-1 antibodies; group 2: inhibition of HMGB-1 releases from the nucleus into the extracellular space; group 3: HMGB-A box as a competitive antagonist of HMGB-1; group 4: blockage of RAGE-HMGB-1 signaling using RAGE antagonists; group 5: blockage of TLR-HMGB-1 signaling using anti-TLR2 antibodies and group 6: other molecules that modulate HMGB-1 activity using e.g. human soluble thrombomodulin. The mechanism of HMGB-1 action, its role and efficiency of each group of patents proposed for controlling inflammation are discussed.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"6 3","pages":"201-9"},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/187221412802481784","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30799214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 84

Perspectives of new therapies for endometriosis. 子宫内膜异位症新疗法的展望。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-09-01 DOI: 10.2174/187221412802481702

Jenny V Garmendia, Juan B De Sanctis

引用次数: 3

Recent patents and developments in glaucoma biomarkers. 青光眼生物标志物的最新专利和进展。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-09-01 DOI: 10.2174/187221412802481739

Basilio Colligris, Almudena Crooke, Xavier Gasull, Julio Escribano, Rocío Herrero-Vanrell, Jose Manuel Benitez-del-Castillo, Julián García-Feijoo, Jesus Pintor

{"title":"Recent patents and developments in glaucoma biomarkers.","authors":"Basilio Colligris, Almudena Crooke, Xavier Gasull, Julio Escribano, Rocío Herrero-Vanrell, Jose Manuel Benitez-del-Castillo, Julián García-Feijoo, Jesus Pintor","doi":"10.2174/187221412802481739","DOIUrl":"https://doi.org/10.2174/187221412802481739","url":null,"abstract":"Glaucoma is an eye condition mainly developed from an excessive intraocular pressure. The condition tends to be inherited and may not show up until later in life. The increased pressure, can damage the optic nerve, provoking loss of vision. Without treatment, glaucoma can cause blindness within a few years; consequently glaucoma has to be diagnosed before long-term visual loss occurs. If it is diagnosed and treated early, the disease can be controlled. Usually, the patient does not notice any early symptoms or pain from this increased pressure, so the early diagnosis is problematic. Over half of the patients with glaucoma are unaware they have this blinding disease and by the time they are diagnosed, they already have irreversibly lost approximately 30-50% of their retinal ganglion cells. Glaucoma diagnosis is currently based on specific signs of the disease, characteristic optic nerve head changes and visual field loss. Thus, improved methods for early diagnosis of glaucoma are needed. Molecular genetics are valuable for the understanding the pathophysiology and cure of glaucoma, but still are not widely used for its diagnosis. Genetic studies on glaucoma have revealed many genes and chromosomal loci associated to glaucoma. Consequently, a better understanding of the molecular mechanisms underlying glaucoma is required to obtain early diagnosis and avoid potential disease progression. In this article, we revise the patents and the corresponding literature on the latest developments and approaches in glaucoma diagnosis, using mainly molecular genetics.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"6 3","pages":"224-34"},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/187221412802481739","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30785637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Therapeutic potential of natural products in Parkinson's disease. 天然产品对帕金森病的治疗潜力。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2012-09-01 DOI: 10.2174/187221412802481793

Rajeswara B Mythri, Gangadharappa Harish, M M Bharath

{"title":"Therapeutic potential of natural products in Parkinson's disease.","authors":"Rajeswara B Mythri, Gangadharappa Harish, M M Bharath","doi":"10.2174/187221412802481793","DOIUrl":"10.2174/187221412802481793","url":null,"abstract":"The central objective in treating patients with Parkinson's disease (PD) is two-fold (i) to increase the striatal dopamine content and (ii) to prevent further degeneration of the surviving dopaminergic neurons in the substantia nigra region of the ventral midbrain. Most of the current PD drugs contribute to the former and provide symptomatic relief. Although compounds such as Levodopa (L-DOPA) improve the striatal dopamine content, their long-term usage is associated with progressive decrease in drug response, motor fluctuations, dyskinesias and drug-induced toxicity. In addition, these drugs fail to prevent the progression of the degenerative process. This has shifted the focus onto alternative therapeutic approaches involving natural products that could provide independent therapy or offer neuroprotective support to the existing drugs. The current review describes the neuroprotective and therapeutic utility of such natural products including herbal extracts, phytochemicals and bioactive ingredients from other natural sources either in isolation or in combination, with potential application in PD, highlighting the relevant patents.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"6 3","pages":"181-200"},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/187221412802481793","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30785582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 36